help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BECKY KELLY, E. A.
Right arrow Articles by JARJOUR, N. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BECKY KELLY, E. A.
Right arrow Articles by JARJOUR, N. N.

Am. J. Respir. Crit. Care Med., Volume 162, Number 3, September 2000, 883-890

Inhaled Budesonide Decreases Airway Inflammatory Response to Allergen

ELIZABETH A. BECKY KELLY, WILLIAM W. BUSSE, and NIZAR N. JARJOUR

Pulmonary and Critical Care Section and Allergy and Immunology Section of the Department of Medicine, University of Wisconsin, Madison, Wisconsin

To define the mechanisms by which inhaled glucocorticosteroid regulates allergen-induced airway inflammation, a double-blind, placebo-controlled, cross-over study with inhaled budesonide was conducted in 14 subjects with allergic asthma. After baseline bronchoscopy and bronchoalveolar lavage (BAL), subjects were randomized to budesonide (400 µg, twice daily) or placebo treatment for 4 wk. At the end of each treatment phase, whole-lung allergen inhalation challenge was performed, followed by BAL 48 h later. Budesonide treatment improved the FEV1, attenuated both the immediate- and late-phase response to allergen, and prevented the increase in bronchial hyperresponsiveness after allergen challenge. Budesonide treatment also decreased allergen-induced airway eosinophilia. To determine the effects of budesonide on airway cell function, BAL cells were stimulated ex vivo with the T cell mitogen PHA, and cytokine generation was measured by ELISA. Budesonide decreased ex vivo generation of IL-5 and IFN-gamma by BAL cells. Ex vivo IL-5 production was significantly correlated with the number of airway eosinophils (rs = 0.61), and levels of eosinophil-derived neurotoxin (EDN) (rs = 0.57) and IL-5 (rs = 0.52) in BAL fluid. Moreover, PHA-induced IL-5 generation correlated with FEV1 fall during the late-phase response to allergen (rs = 0.60). Budesonide decreased circulating eosinophils and serum levels of IL-5, but did not reduce IL-5 generation by peripheral blood mononuclear cells. The reduction in circulating eosinophils correlated with the decrease in levels of EDN (rs = 0.61) in BAL fluid and late response to inhaled allergen (rs = 0.51). These findings suggest that long-term treatment with inhaled budesonide reduces airway cell generation of cytokines, specifically IL-5, which then decreases circulating eosinophils and their availability for recruitment to the airway after allergen exposure.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. W. Johansson, E. A. B. Kelly, W. W. Busse, N. N. Jarjour, and D. F. Mosher
Up-Regulation and Activation of Eosinophil Integrins in Blood and Airway after Segmental Lung Antigen Challenge
J. Immunol., June 1, 2008; 180(11): 7622 - 7635.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
M. E. Bates, L. Y. Liu, S. Esnault, B. A. Stout, E. Fonkem, V. Kung, J. B. Sedgwick, E. A. B. Kelly, D. M. Bates, J. S. Malter, et al.
Expression of Interleukin-5- and Granulocyte Macrophage-Colony-Stimulating Factor-Responsive Genes in Blood and Airway Eosinophils
Am. J. Respir. Cell Mol. Biol., May 1, 2004; 30(5): 736 - 743.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L.-P. Boulet
Asymptomatic Airway Hyperresponsiveness: A Curiosity or an Opportunity to Prevent Asthma?
Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 371 - 378.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Y. Liu, J. B. Sedgwick, M. E. Bates, R. F. Vrtis, J. E. Gern, H. Kita, N. N. Jarjour, W. W. Busse, and E. A. B. Kelly
Decreased Expression of Membrane IL-5 Receptor {alpha} on Human Eosinophils: I. Loss of Membrane IL-5 Receptor {alpha} on Airway Eosinophils and Increased Soluble IL-5 Receptor {alpha} in the Airway After Allergen Challenge
J. Immunol., December 1, 2002; 169(11): 6452 - 6458.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. L. Faul, E. A. Demers, C. M. Burke, and L. W. Poulter
Alterations in Airway Inflammation and Lung Function During Corticosteroid Therapy for Atopic Asthma*
Chest, May 1, 2002; 121(5): 1414 - 1420.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L. ULLER, C. G. A. PERSSON, L. KALLSTROM, and J. S. ERJEFALT
Lung Tissue Eosinophils May Be Cleared Through Luminal Entry Rather Than Apoptosis . Effects of Steroid Treatment
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1948 - 1956.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  2009 ATS Conference Fees